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Body wasting in the context of chronic illness is associated with reduced quality of life and impaired
survival. Recent clinical trials have investigated different approaches to improve patients’ skeletal muscle
mass and strength, exercise capacity, and survival in the context of cachexia and body wasting, many of
them in patients with cancer. The aim of this article was to summarize clinical trials published over the
past 2 years. Therapeutic approaches discussed include appetite stimulants, such as megestrol acetate,
L-carnitine, or melatonin, anti-inﬂammatory drugs, such as thalidomide, pentoxyphylline, or a mono-
clonal antibody against interleukin-1a as well as ghrelin and the ghrelin agonist anamorelin; nutritional
support, and anabolics, such as enobosarm and testosterone.
 2014 AMDA e The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Changes in body composition that occur with chronic diseases are
usually considered unwanted and are associated with loss of skeletal
muscle mass, fat mass, or both.1,2 The loss of lean and fat tissue may
in turn be associated with weight loss. Such involuntary weight loss
has been termed cachexia. Much confusion exists with regard to the
different terminology.3 A recent consensus deﬁnition suggests to
diagnose cachexia when there is loss of more than 5% of body weight
over 12 months or less in the presence of a chronic illness such as
heart failure, chronic obstructive pulmonary disease (COPD), chronic
kidney disease, or cancer,4 altogether providing the basis for an
estimated 9 million subjects being affected by cachexia in industri-
alized countries alone.5 The mere loss of skeletal muscle mass in the
limbs that exceeds 2 SDs of the mean of a healthy young reference
population has been termed sarcopenia.6e8 Some researchers have
suggested to restrict the use of the term sarcopenia to apparently
healthy elderly subjects who lose muscle mass as a consequence of
the aging process. In the context of chronic illness, the terms muscle
wasting, myopenia, or even muscle wasting disease have been used
or proposed.9,10 In contrast to cachexia, sarcopenia and muscle
wasting are not usually associated with weight loss, but with reduced
exercise capacity and reduced quality of life.11 Although the devel-
opment of cachexia is mostly associated with impaired survival, thethe International Journal of
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te and Long-Term Care Medicine. Pdevelopment of sarcopenia can be associated with poor survival as
well. The 2 conditions have seen much attention in recent years: ﬁrst,
with regard to their deﬁnition4,6; second, with regard to their
pathophysiology12e14; and third, with regard to their treatment.15,16
In fact, pathophysiological pathways of the 2 clinical entities can,
but do not necessarily have to, overlap. For clinicians actively
involved in the care of patients at risk of cachexia or muscle wasting
(ie, surgeons, oncologists, nephrologists, cardiologists, and many
more), the available terms often create more confusion than help,
making the diagnosis of cachexia and muscle wasting a rarity.17 This
is unfortunate, in particular because both require medical attention,
and treatment approaches are currently under way that will hope-
fully enable physicians to maintain their patients’ muscle mass and
body weight and therefore their ability to maintain activities of daily
living for longer than is currently possible. The aim of this article was
to highlight clinical intervention trials that have been published over
the past 2 years with the primary purpose of treating cachexia.
Studies that have shown beneﬁcial results in animal experiments
only using approaches such as myostatin blockade,18 use of green
tea,19 ursodeoxycholic acid,20 or inhibition of nuclear factor-kB21 are
not discussed.
Appetite Stimulants
Loss of appetite appears in many patients with cancer, which is
not only frequent, but also associated with poor prognosis and
reduced quality of life. The origin of appetite loss has been deemed
multifactorial, and a recent study failed to show a genetic association
of appetite loss in patients with cancer.22 However, overexpression of
proinﬂammatory cytokines, such as interleukin (IL)-1, IL-6, tumorublished by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
S. von Haehling, S.D. Anker / JAMDA 15 (2014) 866e872 867necrosis factor, or interferon-g, as well as macrophage inhibitory
cytokine-1/growth differentiation factor 15 (MIC-1/GDF-15) appear to
be involved.23,24 Activation of these factors has effects on peripheral
(lipolysis, proteolysis, insulin resistance) as well as on central path-
ways (hypothalamic appetite regulation).23,25 Megestrol acetate, a
synthetic, orally active derivative of the hormone progesterone, was
originally synthesized in 1963 as a contraceptive drug.26 Beginning in
1967, it was used in the treatment of breast cancer. Beginning in 1993,
it was approved in the United States and in several European coun-
tries for the treatment of the anorexia-cachexia syndrome.26 It has
recently been argued that the use of megestrol acetate also may be
helpful in patients with muscle wasting without weight loss.15
Wen et al27 recently studied 102 patients with cancer-related
anorexia/cachexia syndrome who were randomly assigned to
receive, for 8 weeks, either a combination therapy of oral megestrol
acetate at a dosage of 160 mg twice daily plus oral thalidomide 50 mg
twice daily or megestrol acetate 160 mg twice daily alone (all studies
discussed in the text are summarized in Table 1). Patients in either
group showed an increase in their appetite score (both P < .03). The
increase in body weight and the improvement in quality of life were
more pronounced in the group that received combination therapy
than in the group on megestrol acetate alone. Serum values of IL-6
and tumour necrosis factor decreased only in the combination ther-
apy group, just as handgrip strength was only improved in this
group.27 Another small study28 used a combination therapy of oral
formoterol (80 mg/d) and megestrol acetate tablets (480 mg/d) for up
to 8 weeks in 13 patients with advanced malignancy and involuntary
weight loss. Six of 7 patients who completed the study showed an
improvement in muscle size and muscle function as assessed using
quadriceps strength and magnetic resonance imaging. In fact, quad-
riceps volume increased signiﬁcantly (P < .02); in addition, there was
a trend toward an increase in the patients’ quadriceps and handgrip
strength.28
Just as with thalidomide, several workers have tried to enhance
the effects of megestrol acetate on appetite using different ap-
proaches. L-carnitine, for example, plays a central role in fatty acid
metabolism and possesses antioxidant and anti-inﬂammatory prop-
erties.29 Madeddu et al30 randomized 60 patients with advanced
cancer at any site and weight loss of at least 5% to receive either L-
carnitine 4 g per day plus celecoxib 300 mg per day or the same
regimen plus megestrol acetate 320 mg per day. After 4 months of
treatment, no signiﬁcant difference was noted between the 2 treat-
ments with regard to an increase in lean body mass, total daily
physical activity, handgrip strength, or 6-minute walk distance.
However, when the 2 arms were analyzed separately, signiﬁcant in-
creases were noted in each arm for lean body mass (by about 2.5 kg,
both P < .04) and 6-minute walk distance (approximately 50 m, both
P < .04). No change was noted for physical activity or grip strength.
Resting energy expenditure decreased signiﬁcantly in both groups.
Body weight was increased in the group that received megestrol
acetate only (from 54.7  10.8 to 57.2  11.8 kg, P ¼ .05).
L-carnitine on its own also has been successfully used in 72 pa-
tients with advanced pancreatic cancer as part of a prospective,
multicenter, placebo-controlled, randomized, and double-blinded
trial.31 Patients received oral L-carnitine at a dose of 4 g or placebo.
At study entry, patients reported a mean weight loss of 12.0  2.5 kg.
During 12 weeks of treatment, body mass index increased by
3.4%  1.4% under L-carnitine and decreased by 1.5%  1.4% in con-
trols (P < .05). Likewise, body fat and body cell mass increased in the
L-carnitine group only.
The appetite stimulant megestrol acetate also has been success-
fully used in children. Cuvelier et al32 randomized, in a double-blind
fashion, 26 children to receive an oral suspension of megestrol ace-
tate (7.5 mg/kg/d) or placebo for 90 days. Patients enrolled into thestudy were younger than 18 years of age and presented with weight
loss of 5% or more secondary to cancer and/or cancer treatment.
Children on megestrol acetate experienced an average weight gain
of þ19.7% compared with a mean weight loss of 1.2% in the placebo
group (P ¼ .003).32 All patients in the megestrol acetate group
developed at least one undetectable early morning serum cortisol
level during the study; this occurred only in 1 patient on placebo.
Severe adrenal suppression was reported in 2 patients on megestrol
acetate. Other adverse effects were not different between this and the
placebo group.32
Melatonin has been shown to improve appetite in animal exper-
iments.33 Del Fabbro et al34 performed a randomized, placebo-
controlled trial in patients with advanced lung or gastrointestinal
cancer. Unfortunately, the trial was stopped early for futility. This
result came as a surprise, because the dosage used in this trial, oral
melatonin 20 mg at night, was similar to that used in previous trials
and is much higher than that used for conditions such as jet lag
(typically 0.5e5.0 mg). A total of 73 patients were enrolled, but it was
stopped after 48 subjects had ﬁnished the study, because an interim
analysis showed that the interventionwas unlikely to be of signiﬁcant
beneﬁt. In fact, none of the assessed end points improved: the Ed-
monton Symptom Assessment Scale (ESAS), the Functional Assess-
ment of Cancer Illness TherapyeFatigue (FACIT-F), or the Functional
Assessment of Anorexia/Cachexia Therapy (FAACT) scores. Also, there
was no change in body weight to suggest any beneﬁt of melatonin
over placebo (all P > .15).34
Inﬂammation
Inﬂammatory processes have been shown to maintain the
wasting process in cachexia. Hong et al35 used a novel approach to
target inﬂammation and its consequences in patients with advanced
cancer. For this purpose, they designed a dose-escalation and
expansion approach using a ﬁrst-in-class monoclonal antibody
(MABp1) cloned from a human being that targets IL-1a. The ﬁrst,
dose-escalation part of the study identiﬁed an optimal intravenous
dose of 3.75 mg/kg every 2 weeks. Using this dose, the following
phase II study was performed. In the 42 patients in this open-label,
uncontrolled study, median plasma IL-6 concentrations decreased
from baseline to week 8 (P ¼ .08). Of the 34 patients who were re-
staged, 1 patient had a partial response and 10 had stable disease.
Among 30 patients with an assessment of body composition, lean
mass increased signiﬁcantly by 1.02  2.24 kg (P ¼ .02). Overall, the
drug was well tolerated.35
Two recent interventional studies used thalidomide to treat
cachexia. Unfortunately, thalidomide is a drug associated with trag-
edy, because a single dose can induce malformation of the unborn in
pregnant women.36 Despite these effects, it has been rediscovered for
its anti-inﬂammatory properties, and reports dating back more than
20 years have demonstrated successful treatment of erythema no-
dosum leprosum.37 Yennurajalingam et al38 studied 31 patients with
advanced cancer with weight loss of more than 5% in the previous
6 months who also reported anorexia and fatigue. Patients were, in a
double-blinded fashion, randomized to receive 100 mg thalidomide
daily (n ¼ 15) or placebo for a comparatively short duration of
14 days. Only 21 patients completed the study. Statistically signiﬁcant
decreases were noted for fat mass (median: e1.5 kg, P ¼ .03) and fat-
free mass (e4.8 kg, P ¼ .024) after 14 days of treatment with
thalidomide. Some changes with regard to cytokine levels were noted
as well; however, no effect was noted for the ESAS, FAACT, the FACIT-
F, the Hospital Anxiety Depression Scale, or the Pittsburgh Sleep
Quality Index. Another small phase II trial was conducted by Davis
et al39 using 50 mg of thalidomide administered orally at bedtime;
however, this trial was uncontrolled and unblinded. Nonresponders
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then to 200 mg once daily. Of 33 patients with active cancer and loss
of appetite as assessed using a numerical rating scale, 64% showed
improved appetite. In addition, patients’ insomnia and quality of life
categorical scale values increased signiﬁcantly.
Wasting plays a major role not only in patients with cancer, but
also in patients with chronic kidney disease.40 Rattanasompattikul
et al41 randomized 93 patients on maintenance dialysis in a double-
blind fashion to 1 of 4 groups, receiving either (1) 1 can of nutri-
tional support and 1 can of an anti-inﬂammatory, antioxidant
nutrition along with 1 tablet of pentoxyphylline (400 mg, 3 times
weekly), which is known to possess anti-inﬂammatory properties as
well; (2) 2 cans of active nutrition as described before plus a placebo
tablet; (3) 2 cans of nutritional placebo plus a pentoxyphylline tablet;
(4) 2 cans of nutritional placebo plus 1 placebo tablet. At inclusion, all
patients had been hypoalbuminemic for at least the previous
3 months, deﬁned as serum albumin values lower than 4 g/dL. After
16 weeks of treatment, signiﬁcant increases in serum albumin were
found after all 3 interventions, but not in the placebo group. None of
the groups showed a signiﬁcant decline in the inﬂammatory markers
C-reactive protein, IL-1b, or IL-6.41Ghrelin
Ghrelin is a 28-amino acid peptide hormone mostly produced in
the stomach, but also in other gastrointestinal tissues.11,42 It induces
the release of growth hormone from the pituitary gland and stimu-
lates food intake.43,44 Ghrelin also inhibits the production of the
proinﬂammatory cytokines IL-1a, IL-6, and tumor necrosis factor, but
induces the anti-inﬂammatory cytokine IL-10.45 Overall, the meta-
bolic changes induced by ghrelin lead to an increase in body weight
and body fat mass, but also in lean tissue mass, the latter possibly
mediated by a reduction in myostatin plasma levels. Even though
gender-speciﬁc differences have been reported in men and
women,46,47 overall ghrelin plasma levels have been shown to be
decreased in obesity and elevated in cachexia. In addition, ghrelin has
been suggested to link nutrition and reproduction, because animal
experiments have shown that ghrelin administration leads to inhib-
itory responses in the secretion of luteinizing hormone and testos-
terone, thus potentially contributing to hypogonadism.48
Ghrelin administration has therapeutic appeal for its anabolic
activities,49 and ghrelin plasma levels have been assessed in several
observational studies of cachexia in chronic diseases.50e52 Ghrelin
agonists, such as anamorelin, carry potential in the treatment of
cachexia as they mimic a natural ligand for the growth hormone
secretagogue receptor and thus stimulate food intake and appetite.53
Starting in 2004, a small number of interventional studies have used
oral, intravenous, or subcutaneous ghrelin administration45 for the
treatment of wasting in chronic heart failure,54 COPD,55 cancer,56e58
or end-stage renal disease.59,60 The most recent additions to the
ghrelin intervention portfolio have been performed in COPD and
cancer. Miki et al61 performed a multicenter, randomized, double-
blind, controlled trial including 33 cachectic patients with COPD
who were randomly assigned to receive placebo or intravenous
ghrelin at a dose of 2 mg/kg of body weight twice daily for 3 weeks.
Patients on ghrelin treatment displayed an increase in their 6-minute
walking distance after 3 weeks (placebo [m  SE]: þ35  12 m vs
ghrelin: þ40  17 m, both P < .05 vs baseline) that was maintained
out to 7 weeks (placebo: þ47  17 m [P < .05 vs baseline] vs
ghrelin: þ18  11 m). No change was noted in the patients’ peak
oxygen consumption value. Unfortunately, the beneﬁcial ﬁndings on
patients’ 6-minute walk distance could not be pathophysiologically
explained, as there were no changes noted in body weight, total lean
mass, serum IL-6, tumor necrosis factor, or hand grip strength.
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patients with stage 3 or 4 nonesmall cell lung cancer who received
anamorelin in an international, randomized, double-blind, 12-week
phase II study.62 Patients were randomized to placebo (n ¼ 76) or
oral anamorelin 50 mg (n ¼ 76) or 100 mg (n ¼ 73) per day. A
beneﬁcial effect on body weight was observed as early as 1 week
after anamorelin treatment initiation. Over 12 weeks, the group
that received 100 mg anamorelin gained on average 0.14 kg
compared with baseline, whereas mean losses of 0.3 kg and 1.32 kg
occurred in the 50-mg and placebo group (P ¼ .0005). No effect was
noted on hand-grip strength or survival. The larger ROMANA 2
phase III trial that included 495 patients with nonesmall cell lung
cancer was recently ﬁnished, but results have not been reported so
far.63 Garcia et al64 performed a multicenter, double-blind, placebo-
controlled crossover trial that evaluated the effects of anamorelin
in 16 cachectic patients with different cancers. Patients were
randomly assigned to receive oral anamorelin at a dosage of 50 mg
per day or placebo for 3 days. Compared with placebo, treatment
with anamorelin induced signiﬁcant increases in body weight
(placebo: e0.33 kg vs anamorelin: þ 0.77 kg, P ¼ .02), appetite
(P < .02), and serum levels of growth hormone and insulin-like
growth factor-1.Enobosarm and Other Anabolics
Anabolic steroids have been effectively used to treat muscle
wasting65,66; for example, in chronic heart failure where almost 20%
of patients are affected by this problem.67 In patients with heart
failure, low levels of circulating anabolic hormones are associated
with poor outcomes.68,69 The problem with the administration of
anabolic steroids is that their risks often outweigh their potential
beneﬁts. Selective androgen receptor modulators (SARMs) belong to a
relatively new class of therapeutics currently under development that
possesses anabolic properties without adverse effects on prostate,
skin, or hair, frequently associated with testosterone treatment.70,71
Enobosarm, an orally bioavailable nonsteroidal SARM with tissue-
speciﬁc anabolic and androgenic activity, has shown improvements
in lean mass and physical function in healthy younger as well as in
healthy elderly men and postmenopausal women.72 The latter study
was published in 2011, highlighting a large unmet clinical need.1
Recently, collagen VI fragment has been suggested as a marker of
anabolic response that could be useful in patients treated with
SARMs.73
Dobs et al74 conducted a randomized, double-blind, placebo-
controlled phase II trial to assess the efﬁcacy and safety of enobosarm
in 159 male and postmenopausal female patients with cancer who
had lost at least 2% of body weight in the 6 months before random-
ization. Patients were randomized to receive oral enobosarm at a
dosage of 1 (n ¼ 53) or 3 mg (n ¼ 54) or placebo (n ¼ 52) once daily
for up to 113 days at centers in the United States or Argentina. The
primary end point was deﬁned as the change in total lean body mass
from baseline as assessed by dual-energy X-ray absorptiometry
(DEXA). After study termination, signiﬁcant increases in total lean
mass were noted in both enobosarm groups (enobosarm 1 mg: me-
dian 1.5 kg, range e2.1 to 12.6, P ¼ .001 vs baseline, enobosarm 3 mg:
1.0 kg, e4.8 to 11.5, P ¼ .046). The study drug was well tolerated.
POWER (Prevention and treatment Of muscle Wasting in patients
with cancER) was a double-blind, randomized, placebo-controlled
phase III trial of enobosarm 3 mg once daily that aimed to assess
lean body mass and physical function after treatment. Preliminary
results were recently presented in abstract form.75 A total of 641
patients with stage 3 or 4 nonesmall cell lung cancer were ran-
domized into 1 of 2 trials at initiation of ﬁrst-line chemotherapy
(platinum plus taxane or platinum plus nontaxane) plus add-on,consisting of either enobosarm or placebo for 5 months. The study’s
coprimary end points, as assessed after 84 days of treatment, were
physical function response assessed by stair-climb power and
lean body mass as measured by DEXA. Compared with placebo,
enobosarm treatment was associated with an increase in the stair-
climb power and the lean body mass in the platinum plus taxane
treatment arm, whereas in the platinum plus nontaxane arm,
there was only a signiﬁcant increase in the patients’ lean body mass
(all P < .02).
Using intramuscular testosterone replacement, Del Fabbro et al76
performed a randomized, double-blind, placebo-controlled trial
in 29 patients with advanced cancer, low bioavailable testosterone,
and a fatigue score higher than 3 of 10 on the ESAS. Unfortunately,
4 weeks of treatment did not change patients’ FACIT score values
in the testosterone group (n ¼ 13, administered every 2 weeks)
as compared with the placebo group (n ¼ 16). Improvements
were noted in the testosterone group with regard to the Sexual
Desire Inventory score (P ¼ .05) and the patients’ performance
status (P ¼ .02). The authors therefore concluded that “four weeks
of intramuscular testosterone replacement in hypogonadal male
patients with advanced cancer did not signiﬁcantly improve quality
of life.”76
Another novel anabolic agent has recently been tested in a ran-
domized, double-blind, controlled trial. MT-102, also known as
espindolol, is a novel anabolic/catabolic transforming agent that ap-
pears to possess 3 potential pharmacological targets in cancer
cachexia: (1) reduced catabolism through nonselective b-blockade,
(2) reduced fatigue and thermogenesis through central 5-HT1a
antagonism, and (3) increased anabolism through partial b-2 receptor
agonism.77 Animal experiments in 19-month-old male Wistar Han
rats have shown that espindolol can abolish the effects of aging-
associated body and muscle wasting.78 Indeed, although placebo-
treated animals progressively lost body weight, lean and fat mass,
espindolol-treated animals showed increases in all these parameters
without affecting cardiac function. Key regulators of muscle catabo-
lism showed reduced expression under espindolol treatment.
Another animal study showed that the beneﬁcial effects of espindolol
on wasting were more pronounced than those of other beta-
blockers.79 The ACT-ONE trial was designed to test whether MT-102
(espindolol) will positively impact the rate of change of body
weight in cancer cachexia. The trial’s preliminary results were
recently published in abstract form.80,81 It enrolled a total of 87 pa-
tients with nonesmall cell lung cancer or colorectal cancer from 17
centers who were in stage 3 or 4 of the disease. Patients were ran-
domized in a 3:1:2 fashion to 1 of 2 doses of espindolol (10.0 or
2.5 mg twice daily) or placebo and treated for 16 weeks. Only the
higher dose of espindolol improved lean and fat mass. Hand grip
strength increased signiﬁcantly after 16 weeks in the low-dose and
high-dose treatment groups, but stair climbing power and 6-minute
walking distance did not.Conclusions
Muscle wasting and cachexia remain great challenges in clinical
practice. Clinical trials in this ﬁeld remain small, and most are
undertaken in oncology patients. Much research has focused on
appetite stimulation (mostly using megestrol acetate), anti-
inﬂammatory pathways, and anabolics. Ghrelin has shown some
potential in clinical trials as has enobosarm. Results of the POWER
trial with enobosarm, one of the few large-scale trials to improve
muscle mass and function in patients with advanced cancer, are
eagerly awaited. In addition, results of the ACT-ONE trial using
the anabolic/catabolic transforming agent espindolol have shown
promising results.
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